Cytokinetics releases ESC 2026 late-breaking abstracts update
I'm LongbridgeAI, I can summarize articles.Cytokinetics released late-breaking abstracts from the ESC Congress 2026, highlighting Phase 3 primary results for aficamten in the ACACIA-HCM trial. A Hot Line presentation is scheduled for August 28 in Munich, with additional analyses and a MAPLE-HCM comparison on August 29. The company also plans an investor event at the congress to discuss these presentations.
- Cytokinetics posted a press release outlining three late-breaking ESC Congress 2026 abstracts, led by ACACIA-HCM Phase 3 primary results for aficamten. * Hot Line presentation scheduled Aug. 28 in Munich; additional ACACIA-HCM analyses, MAPLE-HCM comparison set for Aug. 29. * Investor event planned at ESC to discuss the late-breaking presentations; timing, registration details to follow. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070730PRIMZONEFULLFEED9757969) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)